Document Detail


Amifostine modulation of bleomycin-induced lung injury in rodents.
MedLine Citation:
PMID:  10348257     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Bleomycin is an effective anticancer agent whose treatment is limited by severe and potentially fatal pulmonary toxicity. This toxicity, characterized by alveolar inflammation and proliferative fibrosis, is mediated by active oxygen species and may result in disruption of the balance between type 2 pneumocyte apoptosis and fibroblast proliferation. The chemoprotectant activity of amifostine (Ethyol; Alza Pharmaceuticals, Palo Alto, CA/US Bioscience, West Conshohocken, PA) is attributed, in part, to the scavenging of active oxygen species. Therefore, it was of interest to study the effects of amifostine on ameliorating the pulmonary toxicities associated with bleomycin in animals. Studies in hamsters and mice demonstrate that pretreatment with amifostine reduces the pulmonary toxicity induced by bleomycin administration. The results of these preclinical studies suggest that amifostine may be clinically beneficial in reducing the severe pulmonary toxicity associated with bleomycin.
Authors:
L Nici; P Calabresi
Related Documents :
19399307 - Amiodarone pulmonary toxicity.
6195947 - Bleomycin-induced changes in the carbon monoxide transfer factor of the lungs and its c...
22892497 - A case in which sarcoma was diagnosed two years after stent placement to treat right il...
15773277 - Patent foramen ovale in scuba divers. a report of two cases and a brief review of the l...
16731147 - Clinically silent cerebral ischemic events after cardiac surgery: their incidence, regi...
2331577 - Impairment of pulmonary endothelium-dependent relaxation in patients with eisenmenger's...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Seminars in oncology     Volume:  26     ISSN:  0093-7754     ISO Abbreviation:  Semin. Oncol.     Publication Date:  1999 Apr 
Date Detail:
Created Date:  1999-06-04     Completed Date:  1999-06-04     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0420432     Medline TA:  Semin Oncol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  28-33     Citation Subset:  IM    
Affiliation:
Division of Pulmonary/Critical Care Medicine, The Rhode Island Hospital, Providence 02903, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amifostine / pharmacology*
Animals
Antimetabolites, Antineoplastic / adverse effects*
Bleomycin / adverse effects*
Cricetinae
Cytoprotection*
Free Radical Scavengers
Lung / drug effects*,  pathology
Male
Mercaptoethylamines / pharmacology
Mice
Oxidation-Reduction
Prodrugs / pharmacology*
Protective Agents / pharmacology*
Pulmonary Fibrosis / chemically induced,  prevention & control
Chemical
Reg. No./Substance:
0/Antimetabolites, Antineoplastic; 0/Free Radical Scavengers; 0/Mercaptoethylamines; 0/Prodrugs; 0/Protective Agents; 11056-06-7/Bleomycin; 20537-88-6/Amifostine; 31098-42-7/WR 1065

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Chemopreventive doses of amifostine confer no cytoprotection to tumor nodules growing in the lungs o...
Next Document:  Pharmacokinetics of amifostine: effects of dose and method of administration.